<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36301107</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Influenza Infection in Ferrets with SARS-CoV-2 Infection History.</ArticleTitle><Pagination><StartPage>e0138622</StartPage><MedlinePgn>e0138622</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01386-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.01386-22</ELocationID><Abstract><AbstractText>Nonpharmaceutical interventions (NPIs) to contain the SARS-CoV-2 pandemic drastically reduced human-to-human interactions, decreasing the circulation of other respiratory viruses, as well. Consequently, influenza virus circulation, which is normally responsible for 3 to 5 million hospitalizations per year globally, was significantly reduced. With the downscaling of the NPI countermeasures, there is a concern for increased influenza disease, particularly in individuals suffering from postacute effects of SARS-CoV-2 infection. To investigate this, we performed a sequential influenza H1N1 infection 4&#x2009;weeks after an initial SARS-CoV-2 infection in ferrets. Upon H1N1 infection, ferrets that were previously infected with SARS-CoV-2 showed an increased tendency to develop clinical signs, compared to the control H1N1-infected animals. A histopathological analysis indicated only a slight increase for type II pneumocyte hyperplasia and bronchitis. Thus, the effects of the sequential infection appeared minor. However, ferrets were infected with B.1.351-SARS-CoV-2, the beta variant of concern, which replicated poorly in our model. The histopathology of the respiratory organs was mostly resolved 4&#x2009;weeks after the SARS-CoV-2 infection, with only reminiscent histopathological features in the upper respiratory tract. Nevertheless, SARS-CoV-2 specific cellular and humoral responses were observed, confirming an established infection. On account of a modest trend toward the enhancement of the influenza disease, even upon a mild SARS-CoV-2 infection, our findings suggest that a stronger SARS-CoV-2 infection and its consequent, long-term effects could have a greater impact on the outcome of disease after a sequential influenza infection. Hence, the influenza vaccination of individuals suffering from postacute SARS-CoV-2 infection effects may be considered an avertible measure for such a scenario. <b>IMPORTANCE</b> During the COVID-19 pandemic, the use of face masks, social distancing, and isolation were effective not only in decreasing the circulation of SARS-CoV-2 but also in reducing other respiratory viruses, such as influenza. With fewer restrictions currently in place, influenza is slowly returning. In the meantime, people who are still suffering from long-COVID could be more vulnerable to an influenza virus infection and could develop a more severe influenza disease. This study provides directions to the effect of a previous SARS-CoV-2 exposure on influenza disease severity in a ferret model. This model is highly valuable to test sequential infections under controlled settings for translation to humans. We could not induce clear long-term COVID-19 effects, as the SARS-CoV-2 infections in the ferrets were mild. However, we still observed a slight increase in influenza disease severity compared to ferrets that had not encountered SARS-CoV-2 before. Therefore, it may be advisable to include long-COVID patients as a risk group for influenza vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilas Boas de Melo</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5015-580X</Identifier><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dijken</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Ven</LastName><ForeName>Koen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7549-5683</Identifier><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijsman</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomersbach</LastName><ForeName>Ang&#xe9;la</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Animal Research Centre, Poonawalla Science Park, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schouten</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Animal Research Centre, Poonawalla Science Park, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kasteren</LastName><ForeName>Puck B</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0003-4369-6055</Identifier><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Brand</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Veterinary Medicine, University Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jonge</LastName><ForeName>J&#xf8;rgen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3167-2435</Identifier><AffiliationInfo><Affiliation>National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">VOC</Keyword><Keyword MajorTopicYN="N">ferret model</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">sequential infections</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>10</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36301107</ArticleId><ArticleId IdType="pmc">PMC9784775</ArticleId><ArticleId IdType="doi">10.1128/spectrum.01386-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alfano V, Ercolano S. 2020. The efficacy of lockdown against COVID-19: a cross-country panel analysis. Appl Health Econ Health Policy 18:509&#x2013;517. doi:10.1007/s40258-020-00596-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40258-020-00596-3</ArticleId><ArticleId IdType="pmc">PMC7268966</ArticleId><ArticleId IdType="pubmed">32495067</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole S, Brendish NJ, Tanner AR, Clark TW. 2020. Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus. Lancet Respir Med 8:e92&#x2013;e93. doi:10.1016/S2213-2600(20)30502-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30502-6</ArticleId><ArticleId IdType="pmc">PMC7581315</ArticleId><ArticleId IdType="pubmed">33289636</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, Zhang T, Wang Q, Xie Y, Peng Z, Zheng J, Qin Y, Zhang M, Lai S, Wang D, Feng Z, Li Z, Gao GF. 2021. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat Commun 12:3249. doi:10.1038/s41467-021-23440-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23440-1</ArticleId><ArticleId IdType="pmc">PMC8167168</ArticleId><ArticleId IdType="pubmed">34059675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Shi Z, Xu H. 2020. Non-pharmaceutical interventions used for COVID-19 had a major impact on reducing influenza in China in 2020. J Travel Med 27. doi:10.1093/jtm/taaa064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taaa064</ArticleId><ArticleId IdType="pmc">PMC7188119</ArticleId><ArticleId IdType="pubmed">32324879</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. 2022. Influenza update No 414.</Citation></Reference><Reference><Citation>Laurie KL, Rockman S. 2021. Which influenza viruses will emerge following the SARS-CoV-2 pandemic? Influenza Other Respir Viruses 15:573&#x2013;576. doi:10.1111/irv.12866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12866</ArticleId><ArticleId IdType="pmc">PMC8242426</ArticleId><ArticleId IdType="pubmed">33955176</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG . 2020. Persistent symptoms in patients after acute COVID-19. JAMA 324:603&#x2013;605. doi:10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B, Boustani K, Ogger PP, Papadaki A, Tonkin J, Orton CM, Ghai P, Suveizdyte K, Hewitt RJ, Desai SR, Devaraj A, Snelgrove RJ, Molyneaux PL, Garner JL, Peters JE, Shah PL, Lloyd CM, Harker JA. 2022. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity 55:542&#x2013;556. doi:10.1016/j.immuni.2022.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.01.017</ArticleId><ArticleId IdType="pmc">PMC8789571</ArticleId><ArticleId IdType="pubmed">35151371</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. 2021. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 18:e1003773. doi:10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, Wang Z, Wei X, Tang J, Li Y, Marlow H, Hughes S, Hammel L, Cox TM, Goddery E, Ayasoufi K, Weiskopf D, Boonyaratanakornkit J, Dong H, Li H, Chakraborty R, Johnson AJ, Edell E, Taylor JJ, Kaplan MH, Sette A, Bartholmai BJ, Kern R, Vassallo R, Sun J. 2021. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol 6:eabk1741. doi:10.1126/sciimmunol.abk1741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk1741</ArticleId><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi SA, Safamanesh S, Ghasemzadeh-Moghaddam H, Ghafouri M, Azimian A. 2021. High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran. J Med Virol 93:1008&#x2013;1012. doi:10.1002/jmv.26364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26364</ArticleId><ArticleId IdType="pubmed">32720703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, Tian J, Zhou P, Deng Y, Shang J. 2020. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol 92:2870&#x2013;2873. doi:10.1002/jmv.26163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26163</ArticleId><ArticleId IdType="pmc">PMC7307028</ArticleId><ArticleId IdType="pubmed">32530499</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B, Kaur P, Reid RJ, Shamoon F, Bikkina M. 2020. COVID-19 and influenza co-infection: report of three cases. Cureus 12:e9852. doi:10.7759/cureus.9852.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.9852</ArticleId><ArticleId IdType="pmc">PMC7437098</ArticleId><ArticleId IdType="pubmed">32832306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozaras R, Cirpin R, Duran A, Duman H, Arslan O, Bakcan Y, Kaya M, Mutlu H, Isayeva L, Kebanli F, Deger BA, Bekeshev E, Kaya F, Bilir S. 2020. Influenza and COVID-19 coinfection: report of six cases and review of the literature. J Med Virol 92:2657&#x2013;2665. doi:10.1002/jmv.26125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26125</ArticleId><ArticleId IdType="pubmed">32497283</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Riveros-Balta AX, Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I, Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D, Finch CL, Frieman MB, Graham BS, Gralinski LE, Guilfoyle K, Haagmans BL, Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra WB, Knezevic I, Krause PR, Kuhn JH, Le Grand R, Lewis MG, Liu WC, Maisonnasse P, McElroy AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B, Rodriguez E, Rogers TF, Salguero FJ, Schotsaert M, Stittelaar KJ, Thibaut HJ, Tseng CT, et al. . 2020. Animal models for COVID-19. Nature 586:509&#x2013;515. doi:10.1038/s41586-020-2787-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2787-6</ArticleId><ArticleId IdType="pmc">PMC8136862</ArticleId><ArticleId IdType="pubmed">32967005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Deng W, Qi F, Lv Q, Song Z, Liu J, Gao H, Wei Q, Yu P, Xu Y, Qu Y, Li F, Xue J, Gong S, Liu M, Wang G, Wang S, Zhao B, Cong B, Qin C. 2021. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduct Target Ther 6:200. doi:10.1038/s41392-021-00618-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00618-z</ArticleId><ArticleId IdType="pmc">PMC8134832</ArticleId><ArticleId IdType="pubmed">34016949</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang AJ, Lee AC, Chan JF, Liu F, Li C, Chen Y, Chu H, Lau SY, Wang P, Chan CC, Poon VK, Yuan S, To KK, Chen H, Yuen KY. 2021. Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus senhances the severity of pneumonia in golden Syrian hamsters. Clin Infect Dis 72:e978&#x2013;e992. doi:10.1093/cid/ciaa1747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1747</ArticleId><ArticleId IdType="pmc">PMC7717201</ArticleId><ArticleId IdType="pubmed">33216851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai L, Zhao Y, Dong J, Liang S, Guo M, Liu X, Wang X, Huang Z, Sun X, Zhang Z, Dong L, Liu Q, Zheng Y, Niu D, Xiang M, Song K, Ye J, Zheng W, Tang Z, Tang M, Zhou Y, Shen C, Dai M, Zhou L, Chen Y, Yan H, Lan K, Xu K. 2021. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res 31:395&#x2013;403. doi:10.1038/s41422-021-00473-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00473-1</ArticleId><ArticleId IdType="pmc">PMC7890106</ArticleId><ArticleId IdType="pubmed">33603116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Lu P, Fan Y, Xia Y, Liu M. 2020. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 92:1549&#x2013;1555. doi:10.1002/jmv.25781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25781</ArticleId><ArticleId IdType="pmc">PMC7228290</ArticleId><ArticleId IdType="pubmed">32196707</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Skarlupka AL, Jang H, Blas-Machado U, Holladay N, Hogan RJ, Ross TM. 2022. SARS-CoV-2 and influenza A virus co-infections in ferrets. J Virol 96. doi:10.1128/jvi.01791-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01791-21</ArticleId><ArticleId IdType="pmc">PMC8906421</ArticleId><ArticleId IdType="pubmed">34936487</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Zhao X, Zhao Y, Li J, Zheng H, Xue M, Guo L, Zhou J, Yang J, Zuo Y, Chen Y, Yang Z, Fan Q, Qin L, Shi H, Liu L. 2021. H1N1 exposure during the convalescent stage of SARS-CoV-2 infection results in enhanced lung pathologic damage in hACE2 transgenic mice. Emerg Microbes Infect 10:1156&#x2013;1168. doi:10.1080/22221751.2021.1938241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1938241</ArticleId><ArticleId IdType="pmc">PMC8205102</ArticleId><ArticleId IdType="pubmed">34060982</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, Zhao Y, Liu P, Liang L, Cui P, Wang J, Zhang X, Guan Y, Tan W, Wu G, Chen H, Bu Z. 2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368:1016&#x2013;1020. doi:10.1126/science.abb7015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7015</ArticleId><ArticleId IdType="pmc">PMC7164390</ArticleId><ArticleId IdType="pubmed">32269068</ArticleId></ArticleIdList></Reference><Reference><Citation>Everett HE, Lean FZX, Byrne AMP, van Diemen PM, Rhodes S, James J, Mollett B, Coward VJ, Skinner P, Warren CJ, Bewley KR, Watson S, Hurley S, Ryan KA, Hall Y, Simmons H, Nunez A, Carroll MW, Brown IH, Brookes SM. 2021. Intranasal infection of ferrets with SARS-CoV-2 as a model for asymptomatic human infection. Viruses 13:113. doi:10.3390/v13010113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010113</ArticleId><ArticleId IdType="pmc">PMC7830262</ArticleId><ArticleId IdType="pubmed">33467732</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Ven K, van Dijken H, Wijsman L, Gomersbach A, Schouten T, Kool J, Lenz S, Roholl P, Meijer A, van Kasteren PB, de Jonge J. 2021. Pathology and immunity after SARS-CoV-2 infection in male ferrets is affected by age and inoculation route. Front Immunol 12:750229. doi:10.3389/fimmu.2021.750229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.750229</ArticleId><ArticleId IdType="pmc">PMC8566349</ArticleId><ArticleId IdType="pubmed">34745122</ArticleId></ArticleIdList></Reference><Reference><Citation>Achdout H, Vitner EB, Politi B, Melamed S, Yahalom-Ronen Y, Tamir H, Erez N, Avraham R, Weiss S, Cherry L, Bar-Haim E, Makdasi E, Gur D, Aftalion M, Chitlaru T, Vagima Y, Paran N, Israely T. 2021. Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity. Nat Commun 12:5819. doi:10.1038/s41467-021-26113-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26113-1</ArticleId><ArticleId IdType="pmc">PMC8492774</ArticleId><ArticleId IdType="pubmed">34611155</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi SA, Safamanesh S, Ghafouri M, Taghavi MR, Mohajer Zadeh Heydari MS, Namdar Ahmadabad H, Ghasemzadeh-Moghaddam H, Azimian A. 2020. Co-infection with COVID-19 and influenza A virus in two died patients with acute respiratory syndrome, Bojnurd, Iran. J Med Virol 92:2319&#x2013;2321. doi:10.1002/jmv.26014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26014</ArticleId><ArticleId IdType="pmc">PMC7272908</ArticleId><ArticleId IdType="pubmed">32410338</ArticleId></ArticleIdList></Reference><Reference><Citation>Enkirch T, von Messling V. 2015. Ferret models of viral pathogenesis. Virology 479&#x2013;480:259&#x2013;270. doi:10.1016/j.virol.2015.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2015.03.017</ArticleId><ArticleId IdType="pmc">PMC7111696</ArticleId><ArticleId IdType="pubmed">25816764</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li Y, Liu Q, Yao Q, Wang X, Zhang H, Chen R, Ren L, Min J, Deng F, Yan B, Liu L, Hu Z, Wang M, Zhou Y. 2021. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov 7:17. doi:10.1038/s41421-021-00249-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00249-2</ArticleId><ArticleId IdType="pmc">PMC7987126</ArticleId><ArticleId IdType="pubmed">33758165</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinheimer VK, Becher A, Tonnies M, Holland G, Knepper J, Bauer TT, Schneider P, Neudecker J, Ruckert JC, Szymanski K, Temmesfeld-Wollbrueck B, Gruber AD, Bannert N, Suttorp N, Hippenstiel S, Wolff T, Hocke AC. 2012. Influenza A viruses target type II pneumocytes in the human lung. J Infect Dis 206:1685&#x2013;1694. doi:10.1093/infdis/jis455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis455</ArticleId><ArticleId IdType="pmc">PMC7107318</ArticleId><ArticleId IdType="pubmed">22829640</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, de Bree GJ, Bulle EB, Aronica EM, Florquin S, Fronczek J, Heunks LMA, de Jong MD, Guo L, du Long R, Lutter R, Molenaar PCG, Neefjes-Borst EA, Niessen HWM, van Noesel CJM, Roelofs J, Snijder EJ, Soer EC, Verheij J, Vlaar APJ, Vos W, van der Wel NN, van der Wal AC, van der Valk P, Bugiani M. 2020. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 1:e290&#x2013;e299. doi:10.1016/S2666-5247(20)30144-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30144-0</ArticleId><ArticleId IdType="pmc">PMC7518879</ArticleId><ArticleId IdType="pubmed">33015653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan KA, Bewley KR, Fotheringham SA, Slack GS, Brown P, Hall Y, Wand NI, Marriott AC, Cavell BE, Tree JA, Allen L, Aram MJ, Bean TJ, Brunt E, Buttigieg KR, Carter DP, Cobb R, Coombes NS, Findlay-Wilson SJ, Godwin KJ, Gooch KE, Gouriet J, Halkerston R, Harris DJ, Hender TH, Humphries HE, Hunter L, Ho CMK, Kennard CL, Leung S, Longet S, Ngabo D, Osman KL, Paterson J, Penn EJ, Pullan ST, Rayner E, Skinner O, Steeds K, Taylor I, Tipton T, Thomas S, Turner C, Watson RJ, Wiblin NR, Charlton S, Hallis B, Hiscox JA, Funnell S, Dennis MJ, et al. . 2021. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. Nat Commun 12:81. doi:10.1038/s41467-020-20439-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20439-y</ArticleId><ArticleId IdType="pmc">PMC7782478</ArticleId><ArticleId IdType="pubmed">33398055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YI, Kim SG, Kim SM, Kim EH, Park SJ, Yu KM, Chang JH, Kim EJ, Lee S, Casel MAB, Um J, Song MS, Jeong HW, Lai VD, Kim Y, Chin BS, Park JS, Chung KH, Foo SS, Poo H, Mo IP, Lee OJ, Webby RJ, Jung JU, Choi YK. 2020. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 27:704&#x2013;709. doi:10.1016/j.chom.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7144857</ArticleId><ArticleId IdType="pubmed">32259477</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, Qu Y, Li F, Lv Q, Wang W, Xue J, Gong S, Liu M, Wang G, Wang S, Song Z, Zhao L, Liu P, Zhao L, Ye F, Wang H, Zhou W, Zhu N, Zhen W, Yu H, Zhang X, Guo L, Chen L, Wang C, Wang Y, Wang X, Xiao Y, Sun Q, Liu H, Zhu F, Ma C, Yan L, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, Wu G, Qin C. 2020. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583:830&#x2013;833. doi:10.1038/s41586-020-2312-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2312-y</ArticleId><ArticleId IdType="pubmed">32380511</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard M, Kok A, de Meulder D, Bestebroer TM, Lamers MM, Okba NMA, Fentener van Vlissingen M, Rockx B, Haagmans BL, Koopmans MPG, Fouchier RAM, Herfst S. 2020. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun 11:3496. doi:10.1038/s41467-020-17367-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17367-2</ArticleId><ArticleId IdType="pmc">PMC7343828</ArticleId><ArticleId IdType="pubmed">32641684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu DK, Kang B, Noh H, Woo SJ, Lee MH, Nuijten PM, Kim JI, Seo JM, Kim C, Kim M, Yang E, Lim G, Kim SG, Eo SK, Choi JA, Song M, Oh SS, Chung HY, Tijsma AS, van Baalen CA, Kwon KS, Lee SY. 2021. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun 578:91&#x2013;96. doi:10.1016/j.bbrc.2021.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.09.023</ArticleId><ArticleId IdType="pmc">PMC8436435</ArticleId><ArticleId IdType="pubmed">34547629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu DK, Song R, Kim M, Kim YI, Kim C, Kim JI, Kwon KS, Tijsma AS, Nuijten PM, van Baalen CA, Hermanus T, Kgagudi P, Moyo-Gwete T, Moore PL, Choi YK, Lee SY. 2021. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem Biophys Res Commun 566:135&#x2013;140. doi:10.1016/j.bbrc.2021.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.06.016</ArticleId><ArticleId IdType="pmc">PMC8180667</ArticleId><ArticleId IdType="pubmed">34119826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich L, Halwe NJ, Taddeo A, Ebert N, Schon J, Devisme C, Trueb BS, Hoffmann B, Wider M, Fan X, Bekliz M, Essaidi-Laziosi M, Schmidt ML, Niemeyer D, Corman VM, Kraft A, Godel A, Laloli L, Kelly JN, Calderon BM, Breithaupt A, Wylezich C, Veiga IB, Gultom M, Osman S, Zhou B, Adea K, Meyer B, Eberhardt C, Thomann L, Gsell M, Labroussaa F, Jores J, Summerfield A, Drosten C, Eckerle IA, Wentworth DE, Dijkman R, Hoffmann D, Thiel V, Beer M, Benarafa C. 2022. Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. Nature 602:307&#x2013;313. doi:10.1038/s41586-021-04342-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04342-0</ArticleId><ArticleId IdType="pmc">PMC8828469</ArticleId><ArticleId IdType="pubmed">34937050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieber CM, Cox RM, Sourimant J, Wolf JD, Juergens K, Phung Q, Saindane MT, Natchus MG, Painter GR, Sakamoto K, Greninger AL, Plemper RK. 2022. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19. bioRxiv. doi:10.1101/2022.02.04.479171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.04.479171</ArticleId><ArticleId IdType="pmc">PMC9338273</ArticleId><ArticleId IdType="pubmed">35906230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Arora P, Gro&#xdf; R, Seidel A, H&#xf6;rnich BF, Hahn AS, Kr&#xfc;ger N, Graichen L, Hofmann-Winkler H, Kempf A, Winkler MS, Schulz S, J&#xe4;ck H-M, Jahrsd&#xf6;rfer B, Schrezenmeier H, M&#xfc;ller M, Kleger A, M&#xfc;nch J, P&#xf6;hlmann S. 2021. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184:2384&#x2013;2393. doi:10.1016/j.cell.2021.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.036</ArticleId><ArticleId IdType="pmc">PMC7980144</ArticleId><ArticleId IdType="pubmed">33794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181:1489&#x2013;1501. doi:10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, Wullimann DJ, Kammann T, Emgard J, Parrot T, Folkesson E, Karolinska C-SG, Rooyackers O, Eriksson LI, Henter JI, Sonnerborg A, Allander T, Albert J, Nielsen M, Klingstrom J, Gredmark-Russ S, Bjorkstrom NK, Sandberg JK, Price DA, Ljunggren HG, Aleman S, Buggert M, Karolinska COVID-19 Study Group . 2020. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183:158&#x2013;168. doi:10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, Goodwin B, Rubiro P, Sutherland A, Wang E, Frazier A, Ramirez SI, Rawlings SA, Smith DM, da Silva Antunes R, Peters B, Scheuermann RH, Weiskopf D, Crotty S, Grifoni A, Sette A. 2021. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep Med 2:100355. doi:10.1016/j.xcrm.2021.100355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100355</ArticleId><ArticleId IdType="pmc">PMC8249675</ArticleId><ArticleId IdType="pubmed">34230917</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. 2020. Defining trained immunity and its role in health and disease. Nat Rev Immunol 20:375&#x2013;388. doi:10.1038/s41577-020-0285-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0285-6</ArticleId><ArticleId IdType="pmc">PMC7186935</ArticleId><ArticleId IdType="pubmed">32132681</ArticleId></ArticleIdList></Reference><Reference><Citation>Debisarun PA, Gossling KL, Bulut O, Kilic G, Zoodsma M, Liu Z, Oldenburg M, Ruchel N, Zhang B, Xu CJ, Struycken P, Koeken V, Dominguez-Andres J, Moorlag S, Taks E, Ostermann PN, Muller L, Schaal H, Adams O, Borkhardt A, Ten Oever J, van Crevel R, Li Y, Netea MG. 2021. Induction of trained immunity by influenza vaccination - impact on COVID-19. PLoS Pathog 17:e1009928. doi:10.1371/journal.ppat.1009928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009928</ArticleId><ArticleId IdType="pmc">PMC8568262</ArticleId><ArticleId IdType="pubmed">34695164</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Li P, Ju X, Rao J, Huang W, Ren L, Zhang S, Xiong T, Xu K, Zhou X, Gong M, Miska E, Ding Q, Wang J, Zhang QC. 2021. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs. Cell 184:1865&#x2013;1883. doi:10.1016/j.cell.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.008</ArticleId><ArticleId IdType="pmc">PMC7871767</ArticleId><ArticleId IdType="pubmed">33636127</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Huang K, Xie D, Lau JY, Shen W, Li P, Wang D, Zou Z, Shi S, Ren H, Wang Y, Mao Y, Jin M, Kudla G, Zhao Z. 2021. In vivo structure and dynamics of the SARS-CoV-2 RNA genome. Nat Commun 12:5695. doi:10.1038/s41467-021-25999-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25999-1</ArticleId><ArticleId IdType="pmc">PMC8478942</ArticleId><ArticleId IdType="pubmed">34584097</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Brand JM, Kreijtz JH, Bodewes R, Stittelaar KJ, van Amerongen G, Kuiken T, Simon J, Fouchier RA, Del Giudice G, Rappuoli R, Rimmelzwaan GF, Osterhaus AD. 2011. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 85:2851&#x2013;2858. doi:10.1128/JVI.01939-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01939-10</ArticleId><ArticleId IdType="pmc">PMC3067945</ArticleId><ArticleId IdType="pubmed">21209108</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>